Find actively recruiting CAR-T cell therapy clinical trials in the UK. Learn how chimeric antigen receptor T-cell therapy is revolutionising treatment for blood cancers and expanding into solid tumours.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
CAR-T cell therapy is a groundbreaking form of immunotherapy where your own T-cells are genetically modified to express a chimeric antigen receptor (CAR) that targets specific proteins on cancer cells. This "living drug" can persist in your body for years, providing ongoing cancer surveillance.
The process involves: 1) Leukapheresis — your T-cells are collected from your blood. 2) Engineering — a disabled virus inserts the CAR gene into your T-cells. 3) Expansion — millions of CAR-T cells are grown in the lab. 4) Lymphodepletion — you receive chemotherapy to make room. 5) Infusion — the engineered cells are returned to your bloodstream where they hunt and destroy cancer cells.
Actively recruiting studies in the United Kingdom
Loading trials from ClinicalTrials.gov...
Currently, CAR-T is approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), B-cell ALL, and follicular lymphoma after at least two prior treatments. Clinical trials are expanding access to earlier treatment lines, other blood cancers, and solid tumours.
CRS occurs when CAR-T cells rapidly multiply and release large amounts of inflammatory cytokines. Symptoms range from fever and fatigue to low blood pressure and organ dysfunction. Most cases are mild (Grade 1-2) and treatable with tocilizumab. Your team will monitor you in hospital for 1-2 weeks after infusion.
Yes. NHS England funds CAR-T for approved indications including DLBCL, ALL, and mantle cell lymphoma. Treatment centres include Great Ormond Street, UCLH, Christie, Birmingham, and others. Clinical trials offer access to newer CAR-T products for additional conditions.
CAR-T Cell Therapy is used across multiple conditions. Select your condition for targeted results.
How does this treatment compare with alternatives?